Complement activation in multiple sclerosis plaques: an immunohistochemical analysis

Lassmann H, Bruck W, Lucchinetti CF: The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007, 17: 210–218. 10.1111/j.1750-3639.2007.00064.x

Weiner HL: A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J Neurol 2008, 255(Suppl 1):3–11.

Ingram G, Hakobyan S, Robertson NP, Morgan BP: Complement in multiple sclerosis: its role in disease and potential as a biomarker. Clin Exp Immunol 2009, 155: 128–139. 10.1111/j.1365-2249.2008.03830.x

Compston DA, Morgan BP, Oleesky D, Fifield R, Campbell AK: Cerebrospinal fluid C9 in demyelinating disease. Neurology 1986, 36: 1503–1506. 10.1212/WNL.36.11.1503

Compston DA, Morgan BP, Campbell AK, Wilkins P, Cole G, Thomas ND, Jasani B: Immunocytochemical localization of the terminal complement complex in multiple sclerosis. Neuropathol Appl Neurobiol 1989, 15: 307–316. 10.1111/j.1365-2990.1989.tb01231.x

Lumsden CE: The immunogenesis of the multiple sclerosis plaque. Brain Res 1971, 28: 365–390. 10.1016/0006-8993(71)90052-7

Gay D, Esiri M: Blood–brain barrier damage in acute multiple sclerosis plaques: An immunocytological study. Brain 1991, 114(Pt 1B):557–572.

Storch MK, Piddlesden S, Haltia M, Iivanainen M, Morgan P, Lassmann H: Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann Neurol 1998, 43: 465–471. 10.1002/ana.410430409

Prineas JW, Kwon EE, Cho ES, Sharer LR, Barnett MH, Oleszak EL, Hoffman B, Morgan BP: Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 2001, 50: 646–657. 10.1002/ana.1255

Lucchinetti CF, Bruck W, Rodriguez M, Lassmann H: Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 1996, 6: 259–274. 10.1111/j.1750-3639.1996.tb00854.x

Breij EC, Brink BP, Veerhuis R, van den Berg C, Vloet R, Yan R, Dijkstra CD, van der Valk P, Bo L: Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol 2008, 63: 16–25. 10.1002/ana.21311

Barnett MH, Parratt JD, Cho ES, Prineas JW: Immunoglobulins and complement in postmortem multiple sclerosis tissue. Ann Neurol 2009, 65: 32–46. 10.1002/ana.21524

Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Bruck W: Acute axonal injury in multiple sclerosis: correlation with demyelination and inflammation. Brain 2000, 123(Pt 6):1174–1183.

Lassmann H: Review: the architecture of inflammatory demyelinating lesions: implications for studies on pathogenesis. Neuropathol Appl Neurobiol 2011, 37: 698–710. 10.1111/j.1365-2990.2011.01189.x

Howell OW, Palser A, Polito A, Melrose S, Zonta B, Scheiermann C, Vora AJ, Brophy PJ, Reynolds R: Disruption of neurofascin localization reveals early changes preceding demyelination and remyelination in multiple sclerosis. Brain 2006, 129: 3173–3185. 10.1093/brain/awl290

Soverchia L, Ubaldi M, Leonardi-Essmann F, Ciccocioppo R, Hardiman G: Microarrays–the challenge of preparing brain tissue samples. Addict Biol 2005, 10: 5–13. 10.1080/13556210412331327803

Mead RJ, Singhrao SK, Neal JW, Lassmann H, Morgan BP: The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J Immunol 2002, 168: 458–465. 10.4049/jimmunol.168.1.458

Ingram G, Hakobyan S, Hirst CL, Harris CL, Pickersgill TP, Cossburn MD, Loveless S, Robertson NP, Morgan BP: Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain 2010, 133: 1602–1611. 10.1093/brain/awq085

Trapp BD, Nave KA: Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008, 31: 247–269. 10.1146/annurev.neuro.30.051606.094313

Ingram G, Hakobyan S, Hirst CL, Harris CL, Loveless S, Mitchell JP, Pickersgill TP, Robertson NP, Morgan BP: Systemic complement profiling in multiple sclerosis as a biomarker of disease state. Mult Scler 2012, 18: 1401–1411. 10.1177/1352458512438238

Gasque P, Dean YD, McGreal EP, VanBeek J, Morgan BP: Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology 2000, 49: 171–186. 10.1016/S0162-3109(00)80302-1

Woyciechowska JL, Brzosko WJ: Immunofluorescence study of brain plaques from two patients with multiple sclerosis. Neurology 1977, 27: 620–622. 10.1212/WNL.27.7.620

Andersson M, Alvarez-Cermeno J, Bernardi G, Cogato I, Fredman P, Frederiksen J, Fredrikson S, Gallo P, Grimaldi LM, Gronning M, Keir G, Lamers K, Link H, Magalhaes A, Massaro AR, Ohman S, Reiber H, Ronnback L, Schluep M, Schuller E, Sindic CJM, Thompson EJ, Trojano M, Wurster U: Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry 1994, 57: 897–902. 10.1136/jnnp.57.8.897

Qin Y, Duquette P, Zhang Y, Talbot P, Poole R, Antel J: Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. J Clin Invest 1998, 102: 1045–1050. 10.1172/JCI3568

Vanguri P, Koski CL, Silverman B, Shin ML: Complement activation by isolated myelin: activation of the classical pathway in the absence of myelin-specific antibodies. Proc Natl Acad Sci U S A 1982, 79: 3290–3294. 10.1073/pnas.79.10.3290

Clark SJ, Perveen R, Hakobyan S, Morgan BP, Sim RB, Bishop PN, Day AJ: Impaired binding of the age-related macular degeneration-associated complement factor H 402H allotype to Bruch's membrane in human retina. J Biol Chem 2010, 285: 30192–30202. 10.1074/jbc.M110.103986

Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H: Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000, 47: 707–717. 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q

Kira J: Autoimmunity in neuromyelitis optica and opticospinal multiple sclerosis: astrocytopathy as a common denominator in demyelinating disorders. J Neurol Sci 2011, 311: 69–77. 10.1016/j.jns.2011.08.043

Ramaglia V, Hughes TR, Donev RM, Ruseva MM, Wu X, Huitinga I, Baas F, Neal JW, Morgan BP: C3-dependent mechanism of microglial priming relevant to multiple sclerosis. Proc Natl Acad Sci U S A 2012, 109: 965–970. 10.1073/pnas.1111924109

Moore CS, Abdullah SL, Brown A, Arulpragasam A, Crocker SJ: How factors secreted from astrocytes impact myelin repair. J Neurosci Res 2011, 89: 13–21. 10.1002/jnr.22482

Nair A, Frederick TJ, Miller SD: Astrocytes in multiple sclerosis: a product of their environment. Cell Mol Life Sci 2008, 65: 2702–2720. 10.1007/s00018-008-8059-5

Gasque P, Singhrao SK, Neal JW, Gotze O, Morgan BP: Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. Am J Pathol 1997, 150: 31–41.

Gasque P, Singhrao SK, Neal JW, Wang P, Sayah S, Fontaine M, Morgan BP: The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: analysis in multiple sclerosis and bacterial meningitis. J Immunol 1998, 160: 3543–3554.

Badar A, DeFreitas S, McDonnell JM, Yahya N, Thakor D, Razavi R, Smith R, Sacks S, Mullen GE: Recombinant complement receptor 2 radiolabeled with [99mTc(CO)3]+: a potential new radiopharmaceutical for imaging activated complement. PLoS One 2011, 6: e18275. 10.1371/journal.pone.0018275

Thurman JM, Kulik L, Orth H, Wong M, Renner B, Sargsyan SA, Mitchell LM, Hourcade DE, Hannan JP, Kovacs JM, Coughlin B, Woodell AS, Pickering MC, Rohrer B, Holers VM: Detection of complement activation using monoclonal antibodies against C3d. J Clin Invest 2013, 123: 2218–2230. 10.1172/JCI65861